Kazia Therapeutics
KZIA
8 hedge funds and large institutions have $680K invested in Kazia Therapeutics in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
60% more funds holding
Funds holding: 5 → 8 (+3)
38% more capital invested
Capital invested by funds: $491K → $680K (+$189K)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$68.2K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$46.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$34.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$5.84K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Renaissance Technologies
New York
| $268K | – | – | – |
|
2
Bank of America
Charlotte,
North Carolina
| $173K | – | – | – |
|
|
3
Morgan Stanley
New York
| $124K | +$68.2K | +175 | +122% |
|
|
VKH
4
Virtu KCG Holdings
New York
| $46K | +$46.4K | +119 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| $35K | +$34.3K | +88 | New |
|
|
CWM
6
Cornerstone Wealth Management
St. Peters,
Missouri
| $25K | +$25.7K | +66 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $8K | -$5.84K | -15 | -44% |
|
8
Creative Planning
Overland Park,
Kansas
| $1K | – | – | – |
|
KZIA Hedge Fund Activity: Q3 2016 in Review
8 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q3 2016, worth a combined $680K — up 38% from $491K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new KZIA positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $68.2K. The largest seller was UBS Group, cutting an estimated $5.84K.
- 8 institutional investors held Kazia Therapeutics (KZIA) as of Q3 2016, up from 5 in Q2 2016.
- Funds reported $680K of Kazia Therapeutics stock for Q3 2016, up 38% quarter-over-quarter.
- 3 funds opened new Kazia Therapeutics positions in Q3 2016 and 0 closed out, a net change of +3 holders.
- The largest Kazia Therapeutics buyer in Q3 2016 was Morgan Stanley, an estimated $68.2K added.
- The largest Kazia Therapeutics seller in Q3 2016 was UBS Group, an estimated $5.84K sold.
Based on aggregated 13F filings for Q3 2016.